secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2024-04-05T23:59:59+00:00
Accession:  0001185185-24-000360
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation
--------------------------------------------------------------------------------

- Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.
- At pre-specified week 2 endpoint, effect size=0.79, suggesting early onset of action.
- Interim results compare favorably to Brexpiprazole's Phase 3 (Cohen's d 0.35, LS mean -5.32).
- Trial ongoing (n=26 interim); final results may differ as enrollment continues in US and Canada.
- IGC-AD1 targets CB1 receptor, neuroinflammation, and inflammasome-3 pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518524000360/0001185185-24-000360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518524000360/igcpharma20240320_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-24-000360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer